Derma Sciences to Participate in the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will participate in a “Fireside Chat” at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum on Thursday, November 19, 2015 at 3:00 p.m. Eastern time. The conference is being held at the Westin Grand Central Hotel in New York City.

To listen to the discussion, investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com or at http://wsw.com/webcast/canaccord20/dsci. An archived audio of the discussion will also be available on Derma Sciences’ website for 90 days.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The Company sells AMNIOEXCEL^® amniotic allograft membrane and AMNIOMATRIX^® amniotic allograft suspension into the $500 million market for skin substitute products. Derma Sciences’ MEDIHONEY® product line is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ^® is a gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB^® for better management of wound exudate, and BIOGUARD^® for barrier protection against microbes and other contaminants. The Company also offers a full product line of traditional dressings.

For more information please visit www.dermasciences.com.